Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex : the OPTiMiSE study. / Demjaha, Arsime; Galderisi, Silvana; Glenthoj, Birthe; Arango, Celso; Mucci, Armida; Lawrence, Andrew; O'Daly, Owen; Kempton, Matthew; Ciufolini, Simone; Baandrup, Lone; Ebdrup, Bjorn H.; Rodriguez-Jimenez, Roberto; Diaz-Marsa, Maria; Martinez Diaz-Caneja, Covadonga; van Rossum, Inge Winter; Kahn, Rene; Dazzan, Paola; McGuire, Philip.

In: Psychological Medicine, Vol. 53, No. 8, 2023, p. 3471-3479.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Demjaha, A, Galderisi, S, Glenthoj, B, Arango, C, Mucci, A, Lawrence, A, O'Daly, O, Kempton, M, Ciufolini, S, Baandrup, L, Ebdrup, BH, Rodriguez-Jimenez, R, Diaz-Marsa, M, Martinez Diaz-Caneja, C, van Rossum, IW, Kahn, R, Dazzan, P & McGuire, P 2023, 'Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study', Psychological Medicine, vol. 53, no. 8, pp. 3471-3479. https://doi.org/10.1017/S0033291722000010

APA

Demjaha, A., Galderisi, S., Glenthoj, B., Arango, C., Mucci, A., Lawrence, A., O'Daly, O., Kempton, M., Ciufolini, S., Baandrup, L., Ebdrup, B. H., Rodriguez-Jimenez, R., Diaz-Marsa, M., Martinez Diaz-Caneja, C., van Rossum, I. W., Kahn, R., Dazzan, P., & McGuire, P. (2023). Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. Psychological Medicine, 53(8), 3471-3479. https://doi.org/10.1017/S0033291722000010

Vancouver

Demjaha A, Galderisi S, Glenthoj B, Arango C, Mucci A, Lawrence A et al. Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. Psychological Medicine. 2023;53(8):3471-3479. https://doi.org/10.1017/S0033291722000010

Author

Demjaha, Arsime ; Galderisi, Silvana ; Glenthoj, Birthe ; Arango, Celso ; Mucci, Armida ; Lawrence, Andrew ; O'Daly, Owen ; Kempton, Matthew ; Ciufolini, Simone ; Baandrup, Lone ; Ebdrup, Bjorn H. ; Rodriguez-Jimenez, Roberto ; Diaz-Marsa, Maria ; Martinez Diaz-Caneja, Covadonga ; van Rossum, Inge Winter ; Kahn, Rene ; Dazzan, Paola ; McGuire, Philip. / Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex : the OPTiMiSE study. In: Psychological Medicine. 2023 ; Vol. 53, No. 8. pp. 3471-3479.

Bibtex

@article{162d0e26fc384c7686cf00a71825a0e1,
title = "Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study",
abstract = "Background Negative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively small patient samples, and the confounding effects of chronic illness and exposure to antipsychotic medication. We sought to address these issues by investigating concurrently grey matter volumes (GMV) and cortical thickness (CTh) in a large sample of antipsychotic-naive or minimally treated patients with First-Episode Schizophrenia (FES). Methods T1-weighted structural MRI brain scans were acquired from 180 antipsychotic-naive or minimally treated patients recruited as part of the OPTiMiSE study. The sample was stratified into subgroups with (N = 88) or without (N = 92) Prominent Negative Symptoms (PMN), based on PANSS ratings at presentation. Regional GMV and CTh in the two groups were compared using Voxel-Based Morphometry (VBM) and FreeSurfer (FS). Between-group differences were corrected for multiple comparisons via Family-Wise Error (FWE) and Monte Carlo z-field simulation respectively at p < 0.05 (2-tailed). Results The presence of PMN symptoms was associated with larger left inferior orbitofrontal volume (p = 0.03) and greater CTh in the left lateral orbitofrontal gyrus (p = 0.007), but reduced CTh in the left superior temporal gyrus (p = 0.009). Conclusions The findings highlight the role of orbitofrontal and temporal cortices in the pathogenesis of negative symptoms of Schizophrenia. As they were evident in generally untreated FEP patients, the results are unlikely to be related to effects of previous treatment or illness chronicity.",
keywords = "Cortical thickness, first-episode psychosis, FreeSurfer, negative symptoms, voxel-based morphometry, GRAY-MATTER ABNORMALITIES, CORTICAL THICKNESS, ANTIPSYCHOTIC TREATMENT, PSYCHOSIS PATIENTS, PREFRONTAL CORTEX, SYNDROME SCALE, BRAIN CHANGES, SURFACE-AREA, LOBE REGIONS, VOLUME",
author = "Arsime Demjaha and Silvana Galderisi and Birthe Glenthoj and Celso Arango and Armida Mucci and Andrew Lawrence and Owen O'Daly and Matthew Kempton and Simone Ciufolini and Lone Baandrup and Ebdrup, {Bjorn H.} and Roberto Rodriguez-Jimenez and Maria Diaz-Marsa and {Martinez Diaz-Caneja}, Covadonga and {van Rossum}, {Inge Winter} and Rene Kahn and Paola Dazzan and Philip McGuire",
year = "2023",
doi = "10.1017/S0033291722000010",
language = "English",
volume = "53",
pages = "3471--3479",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex

T2 - the OPTiMiSE study

AU - Demjaha, Arsime

AU - Galderisi, Silvana

AU - Glenthoj, Birthe

AU - Arango, Celso

AU - Mucci, Armida

AU - Lawrence, Andrew

AU - O'Daly, Owen

AU - Kempton, Matthew

AU - Ciufolini, Simone

AU - Baandrup, Lone

AU - Ebdrup, Bjorn H.

AU - Rodriguez-Jimenez, Roberto

AU - Diaz-Marsa, Maria

AU - Martinez Diaz-Caneja, Covadonga

AU - van Rossum, Inge Winter

AU - Kahn, Rene

AU - Dazzan, Paola

AU - McGuire, Philip

PY - 2023

Y1 - 2023

N2 - Background Negative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively small patient samples, and the confounding effects of chronic illness and exposure to antipsychotic medication. We sought to address these issues by investigating concurrently grey matter volumes (GMV) and cortical thickness (CTh) in a large sample of antipsychotic-naive or minimally treated patients with First-Episode Schizophrenia (FES). Methods T1-weighted structural MRI brain scans were acquired from 180 antipsychotic-naive or minimally treated patients recruited as part of the OPTiMiSE study. The sample was stratified into subgroups with (N = 88) or without (N = 92) Prominent Negative Symptoms (PMN), based on PANSS ratings at presentation. Regional GMV and CTh in the two groups were compared using Voxel-Based Morphometry (VBM) and FreeSurfer (FS). Between-group differences were corrected for multiple comparisons via Family-Wise Error (FWE) and Monte Carlo z-field simulation respectively at p < 0.05 (2-tailed). Results The presence of PMN symptoms was associated with larger left inferior orbitofrontal volume (p = 0.03) and greater CTh in the left lateral orbitofrontal gyrus (p = 0.007), but reduced CTh in the left superior temporal gyrus (p = 0.009). Conclusions The findings highlight the role of orbitofrontal and temporal cortices in the pathogenesis of negative symptoms of Schizophrenia. As they were evident in generally untreated FEP patients, the results are unlikely to be related to effects of previous treatment or illness chronicity.

AB - Background Negative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively small patient samples, and the confounding effects of chronic illness and exposure to antipsychotic medication. We sought to address these issues by investigating concurrently grey matter volumes (GMV) and cortical thickness (CTh) in a large sample of antipsychotic-naive or minimally treated patients with First-Episode Schizophrenia (FES). Methods T1-weighted structural MRI brain scans were acquired from 180 antipsychotic-naive or minimally treated patients recruited as part of the OPTiMiSE study. The sample was stratified into subgroups with (N = 88) or without (N = 92) Prominent Negative Symptoms (PMN), based on PANSS ratings at presentation. Regional GMV and CTh in the two groups were compared using Voxel-Based Morphometry (VBM) and FreeSurfer (FS). Between-group differences were corrected for multiple comparisons via Family-Wise Error (FWE) and Monte Carlo z-field simulation respectively at p < 0.05 (2-tailed). Results The presence of PMN symptoms was associated with larger left inferior orbitofrontal volume (p = 0.03) and greater CTh in the left lateral orbitofrontal gyrus (p = 0.007), but reduced CTh in the left superior temporal gyrus (p = 0.009). Conclusions The findings highlight the role of orbitofrontal and temporal cortices in the pathogenesis of negative symptoms of Schizophrenia. As they were evident in generally untreated FEP patients, the results are unlikely to be related to effects of previous treatment or illness chronicity.

KW - Cortical thickness

KW - first-episode psychosis

KW - FreeSurfer

KW - negative symptoms

KW - voxel-based morphometry

KW - GRAY-MATTER ABNORMALITIES

KW - CORTICAL THICKNESS

KW - ANTIPSYCHOTIC TREATMENT

KW - PSYCHOSIS PATIENTS

KW - PREFRONTAL CORTEX

KW - SYNDROME SCALE

KW - BRAIN CHANGES

KW - SURFACE-AREA

KW - LOBE REGIONS

KW - VOLUME

U2 - 10.1017/S0033291722000010

DO - 10.1017/S0033291722000010

M3 - Journal article

C2 - 35197142

VL - 53

SP - 3471

EP - 3479

JO - Psychological Medicine

JF - Psychological Medicine

SN - 0033-2917

IS - 8

ER -

ID: 316147202